|Videos|June 21, 2023

The Development of Bispecifics-Based Combination Therapies in MM

Author(s)Surbhi Sidana, MD, Melissa Alsina, MD, Maria-Victoria Mateos, MD, PhD

Dr Maria-Victoria Mateos shares her expert perspectives on current efficacy and safety data on combination strategies with bispecifics in relapsed/refractory MM.

Episodes in this series

EP. 1 Patient Case 1: A 68-Year-Old with R/R MM Treated with Teclistamab

EP. 1 Patient Case 1: A 68-Year-Old with R/R MM Treated with Teclistamab

EP. 2 Selecting Patients with MM for Teclistamab and Optimal Sequencing

EP. 2 Selecting Patients with MM for Teclistamab and Optimal Sequencing

EP. 3 Mechanism of Action of Teclistamab in R/R MM and Data Updates

EP. 3 Mechanism of Action of Teclistamab in R/R MM and Data Updates

EP. 4 Managing Side Effects of BCMA-Targeting Bispecifics in R/R MM

EP. 4 Managing Side Effects of BCMA-Targeting Bispecifics in R/R MM

EP. 5 Bispecific Antibodies in Development for the Treatment of R/R MM

EP. 5 Bispecific Antibodies in Development for the Treatment of R/R MM

EP. 6 Treatment with Teclistamab Following Progression on CAR-T in R/R MM

EP. 6 Treatment with Teclistamab Following Progression on CAR-T in R/R MM

EP. 7 Patient Case 2: A 39-Year-Old with Progressive Disease After Initial Response to Teclistamab

EP. 7 Patient Case 2: A 39-Year-Old with Progressive Disease After Initial Response to Teclistamab

EP. 8 Treatment Options for Patients with Disease Progression on BCMA-Targeting Bispecifics

EP. 8 Treatment Options for Patients with Disease Progression on BCMA-Targeting Bispecifics

EP. 9 The Development of Bispecifics-Based Combination Therapies in MM

EP. 9 The Development of Bispecifics-Based Combination Therapies in MM

EP. 10 Patient Case 3: A 52-Year-Old Treated with a Non-BCMA-Targeting Bispecific

EP. 10 Patient Case 3: A 52-Year-Old Treated with a Non-BCMA-Targeting Bispecific

EP. 11 Selecting and Sequencing Non-BCMA-Targeting Bispecifics in MM

EP. 11 Selecting and Sequencing Non-BCMA-Targeting Bispecifics in MM

EP. 12 Recent Data on Non-BCMA Targeting Bispecifics in R/R MM

EP. 12 Recent Data on Non-BCMA Targeting Bispecifics in R/R MM

EP. 13 Closing Thoughts on Bispecific Antibodies and the Future of R/R MM Treatment

EP. 13 Closing Thoughts on Bispecific Antibodies and the Future of R/R MM Treatment

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Related to this article

Updated NCCN Guidelines for multiple myeloma add a dedicated MRD testing framework and expand recommended MRD assessment timepoints.

September 18th, 2026

NCCN Guidelines Strengthen MRD Testing Recommendations in Multiple Myeloma

Updated NCCN Guidelines for multiple myeloma add a dedicated MRD testing framework and expand recommended MRD assessment timepoints.

Treatment Strategies in Multiple Myeloma are Changing: © stock_acc - stock.adobe.com

September 12th, 2026

Debating CAR T-Cell Therapy Vs Bispecifics at First Relapse in Myeloma

Experts discussed whether CAR T cells or bispecific antibodies should be used first in relapsed/refractory multiple myeloma at the 2026 SOHO Annual Meeting.

Trending on CancerNetwork

CELMoDs After T-Cell–Engaging Therapy in Multiple Myeloma

Key Takeaways for Multidisciplinary Lung Cancer Care From WCLC 2026

Neoantigen Vaccine Shows Encouraging Activity in Head and Neck Cancer

NCCN Guidelines Strengthen MRD Testing Recommendations in Multiple Myeloma

What Were the Key Hematologic Oncology Takeaways from SOHO 2026?